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Introduction: Hemorrhage is the principal cause of death in the first few hours following severe injury. Coagulopathy
is a frequent complication of critical bleeding. A network of Italian trauma centers recently developed a protocol to
prevent and treat trauma-induced coagulopathy. A pre-post cohort multicenter study was conducted to assess the
impact of the early coagulation support (ECS) protocol on blood products consumption, mortality and treatment costs.
Methods: We prospectively collected data from all severely injured patients (Injury Severity Score (ISS) >15) admitted
to two trauma centers in 2013 and compared these findings with the data for 2011. Patients transfused with at least 3
units of packed red blood cells (PRBCs) within 24 hours of an accident were included in the study. In 2011, patients
with significant hemorrhaging were treated with early administration of plasma with the aim of achieving a high (≥1:2)
plasma-to-PRBC ratio. In 2013, the ECS protocol was the treatment strategy. Outcome data, blood product consumption
and treatment costs were compared between the two periods.
Results: The two groups were well matched for demographics, injury severity (ISS: 32.9 in 2011 versus 33.6 in 2013)
and clinical and laboratory data on admission. In 2013, a 40% overall reduction in PRBCs was observed, together with a
65% reduction in plasma and a 52% reduction in platelets. Patients in the ECS group received fewer blood products:
6.51 units of PRBCs versus 8.14 units. Plasma transfusions decreased from 8.98 units to 4.21 units (P <0.05), and platelets
fell from 4.14 units to 2.53 units (P <0.05). Mortality in 2013 was 13.5% versus 20% in 2011 (13 versus 26 hospital deaths,
respectively) (nonsignificant). When costs for blood components, factors and point-of-care tests were compared, a
€76,340 saving in 2013 versus 2011 (23%) was recorded.
Conclusions: The introduction of the ECS protocol in two Italian trauma centers was associated with a marked
reduction in blood product consumption, reaching statistical significance for plasma and platelets, and with a non-
significant trend toward a reduction in early and 28-day mortality. The overall costs for transfusion and coagulation
support (including point-of-care tests) decreased by 23% between 2011 and 2013.Introduction
Hemorrhage is the principal cause of death in the first
few hours following severe injury. Coagulopathy is a fre-
quent complication of hemorrhage and may occur in up
to 25% of patients, even before hospital admission [1].
Recently, a multidisciplinary, pan-European group of ex-
perts launched the Stop the Bleeding Campaign [2], a cam-
paign to counteract preventable deaths from uncontrolled* Correspondence: gnardi@scamilloforlanini.rm.it
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unless otherwise stated.bleeding following traumatic injury. The goal of the cam-
paign is to reduce the number of patients who die within
24 hours after hospital admission (due to exsanguination)
by a minimum of 20%. This goal was set in response to
the updated European guidelines for management of
bleeding and coagulopathy [3]. These guidelines recom-
mend that every trauma facility implement an evidence-
based treatment algorithm for the bleeding trauma patient
and promote the use of treatment algorithms to guide
clinical management.
The Italian Trauma Centers Network (TUN) responded
to the recommendations by developing a treatmenthis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 The early coagulation support (ECS) protocol.
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protocol (Figure 1) has been described in detail elsewhere
[4]. It is an integrated part of a comprehensive damage re-
suscitation strategy. It is also based on fluid restriction
and the prohibition of colloids. The ECS strategy has been
formally adopted by several Italian trauma centers. To our
knowledge, this is the first example in Europe of the adop-
tion of the same step-by-step algorithm for the manage-
ment of trauma-induced coagulopathy by a large number
of trauma centers. The centers that cooperated in the de-
velopment of the protocol jointly decided to monitor theimpact of ECS on consumption of blood products, trauma
mortality and morbidity, and financial costs. A multicenter
prospective cohort study with retrospective control was
therefore planned by the TUN steering committee.
We report the preliminary results of the ongoing
study, based on first-year data from the first two trauma
centers that implemented ECS.
Material and methods
Our study was planned as a multicenter prospective co-
hort study with a retrospective control. According to the
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were required to join the study at the same time. How-
ever, the process of adopting the ECS protocol took sig-
nificant and varying amounts of time from hospital to
hospital. On 1 January 2013, only two of the trauma cen-
ters were ready to start the study.
We present the results of the first year of use of ECS
at the first two sites that adopted the protocol: S Camillo
Hospital in Rome and Bufalini Hospital, Cesena, Italy.
Both hospitals are high-volume level I trauma centers
that serve a population of about 2 million each. Data
from the post-ECS adoption period (1 January 2013 to
31 December 2013) and the pre-adoption period (1
January 2011 to 31 December 2011) were compared. In
the pre-adoption period, patients were treated according
to the 2010 European guidelines [5]. Patients with crit-
ical bleeding received plasma as early as possible in a
plasma-to-packed red blood cells (PRBCs) ratio aimed at
1:1. Plasma was thawed soon after the patient was
admitted, although in a limited number of cases the
thawing process could be anticipated based on the pre-
hospital team alert. If required, platelets (PTL) were ad-
ministered with the aim of maintaining the PTL count
≥100,000, as recommended by the guidelines. Coagula-
tion was monitored mainly by means of the traditional
laboratory tests (international normalized ratio, pro-
thrombin time, activated partial thromboplastin time, fi-
brinogen by Clauss method), as point-of-care (POC)
tests were not available. The main characteristics of the
two different treatment and monitoring strategies are
shown in Table 1.
In 2013, patients were treated according to the ECS al-
gorithm. In both institutions, POC rotational thromboe-
lastometry (ROTEM) was systematically used to monitor
coagulation. However, although a blood samples for
POC were collected on admission, the initial treatment
was based only on clinical signs and on the results of the
initial blood gas analysis. Therefore, patients with signs
of severe hypoperfusion received the initial coagulation
support even before the results of the first (basal)Table 1 Main characteristics of the two treatment strategiesa
Treatment strategies Standard treatment (2011)
Fluid resuscitation Crystalloids and colloids
Fluid treatment strategy Permissive hypotension, relative fluid
(except in TBI patients)
Tranexamic acid 1 g + 1 g 8-hr infusion
Initial coagulation support “Initial” plasma at high level (>1:2) pl
Treatment of uncontrolled bleeding Plasma:PRBC ratio (>1:2) Keep PTL >1
Coagulation monitoring Traditional: INR, aPTT, PTL, fibrinogen
aaPTT, Activated partial thromboplastin time; INR, International normalized ratio; PO
brain injury.ROTEM test. According to the ECS protocol, patients
who met one or more of the following criteria (“clinical”
criteria) received a standard dose of fibrinogen concen-
trate (2 g), together with the first units of universal
blood: systolic blood pressure (SBP) <100 mmHg, lactate
≥5 mmol/L, base excess (BE) ≤6 or hemoglobin ≤9 g/dl.
POC tests (ROTEM delta; Tem International, Munich,
Germany) were subsequently used systematically to
monitor coagulation and guide the treatment algorithm.
Plasma was not administered in the early treatment
stage. Permissive hypotension and moderate fluid restric-
tion were recommended until surgical bleeding control
was achieved. However, in cases of prolonged bleeding, if
an increasing number of PRBCs was required and high
volume support was needed, plasma was transfused for
volume and coagulation support. In both study periods,
patients were resuscitated according to a damage control
resuscitation strategy [6] with the aim of limiting the
amount of fluids before surgery. However, whereas in
2011 colloids were allowed, the ECS protocol used in 2013
recommended not to use them. During both time periods,
the administration of tranexamic acid soon after admis-
sion was a mandatory part of treatment [7].
For the purpose of this study, we chose to use for the
control group the data of 2011 rather than those of 2012
to allow a 12-month gap between strategies. This en-
sured that protocols would not overlap and results
would not be skewed.
At both hospitals, data for all severely injured patients
(Injury Severity Score (ISS) >15) admitted to the inten-
sive care unit (ICU) and those who die before they can
be admitted are entered into the trauma center’s data-
base. Trauma patients transfused with at least 3 U of
PRBC within 24 hours of a traumatic injury were identi-
fied via blood banks’ electronic registries as study candi-
dates. Data from the ICU and emergency room electronic
records were matched with the blood bank registries to
confirm the blood units transfused within the study’s time
spans. For patients transferred from other hospitals, trans-
fusion data before referral and/or during transport wereEarly coagulation support (2013)
Crystalloids only
restriction Permissive hypotension, relative fluid restriction
(except in TBI patients)
1 g + 1 g 8-hr infusion
asma:PRBC ratio Fibrinogen 2 g
00,000 Goal-directed treatment
(including plasma:PRBC >1:2 if indicated)
(von Clauss method) Viscoelastic POC
C, Point of care; PRBC, Packed red blood cells; PTL, Platelets; TBI, Traumatic
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about all patients who met the study criteria were entered
into a multicenter database.Inclusion criteria
All severely injured patients admitted directly to the
trauma centers or transferred by another institution
within 6 hours of an accident were candidates for inclu-
sion if they met the following criteria: ISS >15; received
at least 3 U of PRBC within the first 24 hours following
the accident; either admitted to the ICU or died after
hospital admission but before ICU admission, either in the
emergency department or in the operating room (OR).Exclusion criteria
Patients who had a cardiac arrest prior to admission (or
who died en route to the hospital) were excluded. Pa-
tients transferred more than 6 hours after an accident or
with incomplete medical reports were also excluded.Definitions
To allow homogeneous collection of transfusion data,
standard definitions of blood components were used.
Each unit of PRBC has an average volume of 250 (+10%)
ml and a hematocrit of 50% to 60%. The amount of
blood obtained through recovery techniques and rein-
fused was computed considering each 250 ml of blood
reinfused equivalent to 1 U of PRBC. Plasma is available
either as 200 ml/U of pathogen-inactivated plasma
(PlasmaSafe; Kedrion, Barga, Italy) or as single-donor
apheresis plasma (600 ml/U). For the purposes of this
study, 200 ml of plasma are considered equal to 1 U.
PTL are available either as single-donor apheresis or as
multiple-donor packs. For the purpose of this study, a
single-donor pack is considered equal to six multiple-
donor packs. Fibrinogen (Haemocomplettan; CSL-Behring,
Marburg, Germany) is available as a 1-g lyophilized, puri-
fied human concentrate. Fibrinogen concentrate is not
available on the market in Italy, and hospitals are supplied
with limited amounts on the basis of authorization from
the Italian Medicines Agency at a fixed price of €400/1 g.
Industrial plasma costs on average €75/200 ml. There is
no established commercial price for PRBC and PTL. How-
ever, a reference cost is based on current published figures
[8,9]: €186 for 1 U of PRBC and €115 for 1 U of PTL
concentrate.
All causes of death were included. Mortality within the
first 24 hours was mainly due to hemorrhage. Patients
meeting the inclusion criteria who subsequently devel-
oped brain death were considered dead after 24 hours if
the organ harvesting took place more than 24 hours
after the accident in a heart-beating donor.Statistical analysis
Distribution of the data was tested with the Kolmogorov–
Smirnov test. Data are presented as mean with standard
deviation or median with interquartile range, depending
on the underlying distribution. Continuous variables were
compared using the Mann–Whitney U test or Student’s
t-test, depending on the underlying distribution. For cat-
egorical variables, the χ2 test was used. A P-value <0.05
was considered significant.
The study was approved by the Ethics Committee
Lazio 1 as a prospective observational study with a
retrospective control. It was determined to waive pa-
tients’ consent because in 2013 the ECS protocol was the
standard of care in the two institutions, after being for-
mally approved by the directors of both hospitals.
Results
A substantially equal number of severely injured patients
were admitted to the two trauma centers in 2011 and
2013 (435 and 431, respectively). However, 30% fewer
patients required transfusion of ≥3 U of PRBCs during
the first 24 hours in 2013 (n = 96) than in 2011 (n = 130).
Patients in the two periods were well matched in terms
of demographics, physiologic parameters on admission,
anatomic severity index and laboratory data (Table 2).
Seventy percent of the patients in both groups were taken
directly from the accident to the trauma center, with an
average admission time of 69 minutes (±20 minutes). In
2011, patients received an average of 8.14 U of PRBCs
versus 6.51 U in 2013 (nonsignificant), with an overall
decrease in blood consumption from 1,048 U to 625 U
(−40%) (Table 3). In 2011, 33 patients required massive
transfusions (MTs), defined as ≥10 U of PRBC) versus 16
in 2013. The average number of PRBC transfused into
the MT patients was 17.8 U in 2011 versus 14.9 U in
2013. The average amount of plasma transfused to the
patients in the study groups was reduced from 8.98 U to
4.21 U (P <0.05), for an overall 65% reduction from 1,167
U to 405 U. The plasma-to-PRBC ratio decreased in
2013 if compared with 2011 for each amount of PRBC
transfused (Table 4). The average amount of PTL trans-
fused was reduced from 4.14 U to 2.53 U (P <0.05), an
overall 52% reduction in PTL consumption from 538 U
to 258 U. In 2013, 134 g of fibrinogen concentrate were
used by the two hospitals. Fibrinogen was not used in
2011.
In 2011, 26 (20%) of 130 patients died within 28 days
following their accidents, and 8 of them died as a result
of exsanguination in the first 24 hours. In the 2013
group, 13 (13.5%) of 96 patients died within 28 days, and
3 patients died within the first 24 hours. The difference
in mortality between the two periods was not statistically
significant. Of the 49 MT patients, 14 died: 10 (30%) of
33 in 2011 and 4 (25%) of 16 in 2013.
Table 2 Patient characteristicsa
2011 2013 Missing P-value
Patients with ISS >15 and ≥3 U of PRBC 130 96
Age, yr Mean (SD) 48.8 (±19.6) 51.1 (±21.6) – 0.436
Sex n (%) M 95 (73.1%) 65 (67.7%) – 0.459
F 35 (26.9%) 31 (32.3%)
Direct admission/referral n (%) Direct admission 89 (68.5%) 68 (70.8%) – 0.770
Referral 41 (31.5%) 28 (29.2%)
Clinical data
GCS score Median (IQR) 14 (9) 13 (8.5) 1 0.608
SBP, mmHg Mean (SD) 108.5 (±32.0) 104.9 (±29.9) 1 0.482
Anatomical injury score
ISS Median (IQR) 32.5 (16) 33 (18) – 0.702
Mean (SD) 32.9 (±11.4) 33.6 (±12.1)
AIS head Median (IQR) 2 (4) 3 (4.5) – 0.343
Mean (SD) 2.2 (±2.1) 2.4 (±2.0)
AIS face Median (IQR) 0 (0) 0 (0) – 0.839
Mean (SD) 0.51 (±1.0) 0.44 (±0.9)
AIS chest Median (IQR) 3 (4) 3 (3.5) – 0.777
Mean (SD) 2.6 (±1.8) 2.5 (±1.8)
AIS abdomen Median (IQR) 2 (3) 0 (3) – 0.036
Mean (SD) 1.83 (±1.7) 1.36 (±1.7)
AIS pelvis and limbs Median (IQR) 3 (3) 3 (1) – 0.138
Mean (SD) 2.1 (±1.6) 2.5 (±1.6)
AIS extremities Median (IQR) 0 (1) 0 (0) – 0.05
Mean (SD) 0.36 (±0.6) 0.19 (±0.6)
Laboratory data
pH Mean (SD) 7.32 (±0.1) 7.29 (±0.1) 56 0.398
Lactate mmol/L Mean (SD) 3.15 (±1.7) 3.18 (±2.7) 52 0.094
BE Mean (SD) −4.47 (±3.5) −4.96 (±5.0) 63 0.997
Hb, g/dl Mean (SD) 10.8 (±2.4) 11.2 (±2.1) 13 0.240
PTL, μl Mean (SD) 196.6 (±70.9) 205.3 (±77.4) 53 0.439
INR Mean (SD) 1.40 (±0.5) 1.38 (±0.6) 24 0.408
FIB (von Clauss method), mg/100 ml Mean (SD) 184 (±92.8) 196.0 (±85.4) 69 0.276
aAIS, Anatomical injury score; BE, Base excess; FIB EXTREMITIES, Fibrinogen; GCS, Glasgow Coma Scale; Hb, Hemoglobin; INR, International normalized ratio; IQR,
Interquartile range; ISS, Injury Severity Score; PRBC, Packed red blood cells; PTL, Platelets; SBP, Systolic blood pressure; SD, Standard deviation.
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Table 5. Compared with 2011, 2013 saw an overall 48%
reduction from €326,818 to €170,220, for a savings of
€156,598. The additional cost of fibrinogen was €53,600.
The cost for POC tests was €26,663 in 2013 compared
with zero in 2011. However, these data also include the
cost of tests performed for all bleeding patients in the
OR and ICU, so POC test costs for study patients are
overestimated. The average cost for blood components
was €2,528.80 for each treated patient in the 2011 group
versus €1,492.60 in 2013. Including charges for POC
tests and fibrinogen, the average cost per patient in 2013was €2,322, which is still €206 less than the average cost
in 2011.
Discussion
The timely identification of patients who need aggressive
hemostatic resuscitation remains challenging [10,11].
The ECS protocol is activated whenever significant un-
controlled bleeding is associated with one or more of
the following criteria: SBP <100 mmHg, BE less than −6,
lactate >5 mmol/L and/or hemoglobin <9 g/dl. These
criteria were chosen by the TUN panel of experts based
on data in the literature and on a retrospective analysis
Table 3 Impact of introduction of early coagulation support protocol on consumption of blood componentsa
2011 2013 Missing P-value
Patients with ISS >15 and ≥3 U of PRBC 130 96
Blood components transfused within 24 hr
PRBC (U) Mean (SD) 8.09 (6.7) 6.5 (4.8) – 0.149
Median (IQR) 5 (6.0) 4 (5.5)
PTL (U) Mean (SD) 4.18 (5.9) 2.68 (4.75) – 0.046
Median (IQR) 0 (6) 0 (6)
Plasma (U) Mean (SD) 8.97 (9.47) 4.21 (4.61) – <0.001
Median (IQR) 6 (8) 4 (6)
Outcome
Dead within 24 hr n (%) 8 (6.15%) 3 (3.12%) – 0.361
Hospital mortality n (%) 26 (20.0%) 13 (13.5%) – 0.218
aIQR, Interquartile range; ISS, Injury Severity Score; PRBC, Packed red blood cells; PTL, Platelets; SD, Standard deviation.
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in many patients who sustain a severe trauma, and low
fibrinogen levels are associated with higher transfusion
requirements and increased mortality [12]. Recently,
Schlimp et al. [13] demonstrated that levels of fibrino-
gen <150 mg/dl are detected in as many as 73% of pa-
tients with admission hemoglobin <10 g/dl and in 63%
of those with a BE less than −6. Moreover, Brohi and
colleagues [14] found low fibrinogen in 41% of patients
who were hypotensive on admission. Thus, the ECS cri-
teria might well identify patients at high risk of hypofi-
brinogenemia. According to the ECS strategy, bleeding
patients with evidence of severe hypoperfusion should
receive a standard dose of 2 g of fibrinogen immediately.
The decision to start coagulation support with fibrino-
gen before plasma infusion differs substantially from the
standard clinical practice. In the Activation of Coagula-
tion and Inflammation in Trauma (ACIT) study [15],
cryoprecipitate was administered only after the first 6 U
of blood and after infusion of the first units of plasma.
In the PRospective Observational Multicenter Major
Trauma Transfusion (PROMMTT) study, the median
time from admission to first cryoprecipitate unit admin-
istered was 2.7 hours [16]. In the ECS group, fibrinogen
was always administered before plasma was started. ATable 4 Changes in plasma-to-packed red blood cells ratio for
and after introduction of early coagulation supporta
Study year 3 U
2011 Patients, n (%) 32 (25%)
Average plasma units 3.4
Plasma:PRBC ratio 1:1
2013 Patients, n (%) 25 (26%)
Average plasma units 1.3
Plasma:PRBC ratio 1:2.8
aPRBC, Packed red blood cells; PTL, Platelets.similar strategy is recommended in the Austrian guide-
lines [17]. However, the Austrian guidelines also recom-
mend the early use of thromboelastometry to detect
hypofibrinogenemia and guide treatment from the be-
ginning. This strategy might not always be feasible at
many Italian trauma centers, owing to a lack of re-
sources and organizational limitations. Therefore, the
ECS strategy supports the initial “blind” administration
of fibrinogen to avoid any potentially dangerous delay.
In the 2013 group, 50 (52%) of 96 patients met the ECS
criteria for an immediate dose of fibrinogen. These data
are consistent with the Schöchl et al. study [18], in
which 52% of patients qualified on the basis of viscoelas-
tic tests and received their first dose of fibrinogen within
1 hour of admission. However, in contrast to the Schöchl
et al. study the first dose of fibrinogen in our present
study was administered to half of these patients, before
the results of the basal ROTEM test were available and
within 30 minutes of admission. Restoring or increasing
fibrinogen levels may improve the clotting process, thus
allowing a reduction in the amount of allogeneic blood
components transfused. Plasma is currently used as a
source of fibrinogen. However, although administration
of plasma may stabilize fibrinogen levels and avoid a fur-
ther decrease, plasma transfusions cannot produce aeach amount of packed red blood cells transfused before
4 to 5 U 6 to 7 U 8 to 10 U >10 U
39 (30%) 17 (13%) 10 (7%) 33 (25%)
4.2 5.4 8.3 22.1
1:1 0.8:1 1:1 1.2:1
33 (34%) 10 (10%) 12 (13%) 16 (17%)
2.4 3.4 6.6 10.6
1:2 1:2 0.8:1 0.7:1
Table 5 Estimated cost for blood, blood components, factors and point-of-care tests over the two periods (2011 versus
2013)
Estimated cost for 1 U 2011 2013
Units (N) Overall Units (N) Overall
PRBC €186 1,048 €194,928 625 €116,250
Plasma €60 1,167 €70,020 405 €24,300
PTL €115 538 €61,870 258 €29,670
Overall €326,818 €170,220
Balance −€156,598
Fibrinogen €400 (1 g) 0 0 134 g €53,600
POC tests 0 0 €26,663
Overall 0 0 +€80,263
Balance −€76,335
aPOC, Point of care; PRBC, Packed red blood cells; PTL, Platelets.
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volumes are infused [19]. The ACIT study confirmed
these findings [15].
In our study, the number of severe trauma patients
(ISS >15) who received ≥3 U of blood was 30% lower in
2013 than in 2011. This difference was independent of
any change in the number of major trauma admissions
to the two trauma centers and any change in the severity
index of the admitted patients. In 2011, immediate ad-
ministration of plasma to bleeding patients was the
cornerstone of coagulation support. The plasma-to-
PRBC ratio in 2011 was approximately 1:1 for each
amount of PRBC transfused (Table 4). Early and aggres-
sive administration of plasma may result in diluting the
blood cells with a decrease in hemoglobin level [20].
This may also reduce PTL marginalization with a poten-
tially negative impact on PTL activation. Moreover, as 7
to 9 g/dl hemoglobin was the transfusion trigger pro-
posed in the 2010 European guidelines [5], the 2011
plasma-based strategy might have triggered a higher






3 PRBC 4-5 PRBC 6-7 PRBC 8-10 P
Plasma Units
Figure 2 Changes in the number of plasma units transfused related to
of early coagulation support. PRBC, Units of packed red blood cells.of patients who received ≥3 U of PRBC. The data on
plasma transfusion support this hypothesis. Among the
patients transfused with 3 U of blood, the percentage of
those who received plasma decreased by more than half in
2013 compared with 2011 (27% versus 56%, respectively),
and the average number of units of plasma used in 2013
was less than one-third that used in 2011 (1.2 versus 4.1,
respectively). In 2013, the overall number of PRBC units
was reduced by 40%, plasma units by 65% and PTL by
52%. Two different reasons are believed to have contrib-
uted to the observed decrease in the consumption of
blood components: fewer patients who met the study cri-
teria in 2011 compared with 2013 and a reduction in the
average amount of PRBCs, plasma and PTL received by
each one of the patients in the 2013 group. This difference
was statistically significant for plasma and PTL. We ob-
served a consistent reduction of the plasma-to-PRBC ratio
for each amount of PRBC transfused (Figure 2). Data in
the literature show that early and aggressive plasma trans-
fusion improves the survival of trauma patients with crit-
ical bleeding [21-23]. However, availability of pre-thawedRBC > 10 PRBC
2011
2013
the amount of packed red blood cells before and after introduction
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ing early plasma transfusion more a wish than a reality
[24]. The average time to start plasma administration in
the patients in our 2011 control group was 67 (8-90) mi-
nutes. Therefore, the administration of factors as recom-
mended by the ECS protocol might significantly anticipate
coagulation support. If fibrinogen concentrate is adminis-
tered to increase fibrinogen level, there might be less need
to transfuse plasma as a source of fibrinogen. Therefore,
the lower plasma-to-PRBC ratio we observed in 2013 may
be a consequence of the ECS strategy.
In our study, both early mortality and hospital mortal-
ity were lower in 2013 than in 2011 (3.12% versus 6.15%
for early mortality and 13.5% versus 20.0% for hospital
mortality, respectively). However, these are only prelim-
inary data, and the study is not sufficiently powered to
demonstrate statistically significant differences. The ob-
served mortality compares favorably with the recent data
from the PROMMTT study [25] (21.4%), although the
PROMMTT study included patients transfused with as
little as 1 U of PRBC and thus the average ISS was lower
(26.4%). Patients who undergo MT have a high mortality
rate. Mortality rates ranging between 25% [26] and 50%
[27-30] have been reported previously, with lower mor-
tality for patients who received a high ratio of plasma to
PRBC. MT patients in our study had a mortality rate
ranging from 30% in 2011 to 25% in 2013. Patients in
both groups received a high ratio of plasma to PRBC, al-
though in 2011 they received twice as many plasma
units as in 2013. This greatly reduced the economic
costs of patient care, one of the key focal areas of our
study. Görlinger et al. [31] demonstrated that goal-
directed coagulation therapy based on POC monitoring,
together with the use of factors, was associated with a
sharp reduction in plasma and PRBC transfusions and a
€200,000 decrease in the amount spent on blood prod-
ucts per year. Our findings indicate that the cost of
blood and blood components was reduced by 48% in
2013 compared with 2011, for an estimated savings of
more than €150,000 for the two study hospitals. Even
taking into account the additional costs of fibrinogen
and POC tests, there was still a savings of more than
€76,000. Moreover, in Italy, there is a severe shortage of
blood; therefore, saving blood and blood components
has relevance independent of the economic impact.
Our study has several limitations. First, it is not a ran-
domized controlled trial. Large, well-conducted studies
with pragmatic endpoints are required to improve un-
derstanding of the complex interplay between bleeding
and coagulopathy, transfusion requirements and mortal-
ity. However, these studies are extremely costly, which
hinders their feasibility. For this reason, even the most
recent recommendations for prevention and treatment
of trauma coagulopathy could be based only on theresults of observational studies. Our study shows that the
introduction of a strategy based on ECS by means of fac-
tors administration, together with the use of viscoelastic
POC and the ban of the use of colloids, was associated
with a reduction in the need for blood and blood compo-
nents. However, we were not able to define which of these
contributed to the achievement of the results for each of
the different components of the ECS strategy.
A restrictive fluid resuscitation protocol was used in
both periods, although colloids were allowed in 2011
and not in 2013. The 2011 patients received 801 (±545)
ml of 130.4 hydroxyethyl starch (HES) (Voluven; Fresenius
Kabi, Bad Homburg, Germany) as an average. Gelatins
were not used at all. HES may impair coagulation [32,33]
and encourage bleeding, thus increasing the need for
transfusion. Therefore, the choice to avoid colloids accord-
ing to the 2013 ECS strategy might have had a relevant
role in reducing iatrogenic coagulopathy.
In the ECS group, ROTEM was used to monitor co-
agulation. When POC is used, the finding of normal
viscoelastic curves may support a more conservative ap-
proach to plasma transfusion [34]. The systematic use of
thromboelastometry POC by the two trauma centers
was introduced together with the ECS protocol as an in-
tegrated part of the same strategy. Therefore, the possi-
bility to monitor coagulation by means of POC tests is a
relevant difference between the 2011 and 2013 strategies.
A sharp reduction in patient exposure to allogeneic blood
products after the introduction of a thromboelastometry-
guided coagulation factor concentrate-based therapy has
been reported previously by Schöchl et al. [35]. Therefore,
on the basis of our results, we cannot state that the early
administration of fibrinogen itself, if not associated with
the other part of the strategy, is superior to the immediate
administration of plasma, which is also recommended in
the 2013 European guidelines. Despite the constraints of
being an observational study, the results of the present
study come from strictly controlled data, thanks to the
existing electronic ICU records and blood bank databases.
It must be stressed that the data presented here are just
the preliminary results. For a better understanding of the
impact of the ECS strategy, more data on morbidity (inci-
dence of sepsis, acute respiratory distress syndrome, renal
failure) and ICU and hospital lengths of stay are needed.
The collection of these data is part of the study project.
The analysis is ongoing and will be available within the
next few months. The research study continues to involve
more institutions, and it is hoped that the increasing num-
bers of patients included in the study will overcome some
of the current limitations.
Conclusions
TUN recently developed a treatment protocol for bleed-
ing trauma patients called early coagulation support.
Nardi et al. Critical Care  (2015) 19:83 Page 9 of 10The ECS protocol must be considered as part of a com-
prehensive damage resuscitation control strategy. The
introduction of the ECS protocol in two Italian trauma
centers was associated with a marked reduction in blood
product consumption, reaching statistical significance
for plasma and PTL, and with a non-significant trend to-
ward a reduction in early and 28-day mortality. The
overall costs of transfusion and coagulation support (in-
cluding POC tests) decreased by 23%. These data need
to be confirmed with an adequate number of patients.
This is the aim of a larger, ongoing multicenter study.
Key messages
 In every hospital, there is a need for protocols for
managing critical bleeding and prevention of
coagulopathy.
 The use of the early coagulation support protocol
developed by the Italian Trauma Centers Network
was associated with a marked reduction in the
consumption of blood and blood components, with
an associated cost saving.
 There is a strong need for controlled trials to
confirm these data.
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